News

American association of cancer research highlights article published by PHI collaborators

In the October issue of Molecular Cancer Therapeutics the American Association of Cancer Research (AACR) highlights the novel nano­medicine against ovarian cancer developed by scientists from the Center for Pharma­ceutical Bio­tech­nology …
Read More

Lab of Nobel Price winner purchases HoloMonitor

The Department of Optical Nanoscopy (Prof. Stefan W. Hell) at the German Cancer Research Center (DKFZ) in Heidelberg recently ordered a motorized HoloMonitor M4. Professor Hell was awarded the Nobel Prize …
Read More

PHI receives significant order

PHI has received a follow-up order for a minimum of eight motorized HoloMonitor M4 instruments, continuing the strong business performance in the Chinese market. The total customer list price of the ordered …
Read More

HoloMonitor technology facilitates cancer research at Florida International University

Prof. Roy flanked by Dr. Quentin Felty and Dr. Jayanta Das in front of their poster at AACR The first results of the ongoing collaboration between the Department of Environmental and Occupational …
Read More

Nature publishes new HoloMonitor article, PHI achieves 50 publications

Researchers at Chinese Academy of Sciences have used HoloMonitor®technology from PHI to investigate cell behavior when Earth’s magnetic field is eliminated. The findings were recently published in Scientific Reports – an …
Read More

Cell laboratory at Japanese University orders third HoloMonitor

One of the cell laboratories at Kyushu University in Japan has ordered two HoloMonitor® instruments to complement the instrument previously purchased by the laboratory. The university is one of the seven …
Read More

Nature publish HoloMonitor Research

Cells cultivated on nanowires, imaged by HoloMonitor Researchers at Lund University have used Holo­Monitor® technology from Phase Holo­graphic Imaging to investi­gate the behavior of cells when culti­vated on nanowires. The findings …
Read More

PHI and Boston Children’s Hospital enter evaluation agreement

PHI and Boston Children’s Hospital – a Harvard Medical School teaching hospital – have signed an agreement to evaluate PHI’s HoloMonitor®technology for applications in cell-based cancer research.
Read More

PHI achieves market acceptance goals

Prior to the company’s IPO in early 2014, three market acceptance goals were set out to be achieved by the end of 2015: 50 units in operation at customers and key …
Read More

Big Pharma embraces HoloMonitor technology from PHI

Upon completion of an extensive evaluation in early September one of the top pharmaceutical companies in the world has decided to acquire two Holo­Monitor® instruments. The ordered configuration is an automated version …
Read More